The Claim
In patients with acute coronary syndrome, the addition of ezetimibe to statin therapy reduces the incidence of major adverse cardiovascular events over a 7-year period, with a Kaplan-Meier event rate of 32.7% in the combination group compared to 34.7% in the statin-only group, primarily due to reductions in non-fatal myocardial infarction and stroke, without an increase in cancer, gallbladder, or liver-related adverse events.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people who've had a recent heart problem, taking ezetimibe with their cholesterol medicine (a statin) helps prevent heart attacks and strokes over 7 years — and doesn't seem to cause extra cancer or liver issues.
See the scientific wording
Adding ezetimibe to statin therapy in patients with acute coronary syndrome reduces major adverse cardiovascular events (MACE) over 7 years, with a Kaplan-Meier event rate of 32.7% in the combination group versus 34.7% in the statin-only group, driven primarily by reductions in non-fatal myocardial infarction and stroke, without increasing cancer, gallbladder, or liver-related adverse events.
Score breakdown, mechanism chain, raw evidence, ideal studies needed
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.